Literature DB >> 35848174

[Research on three-dimensional printing technology based on three-dimensional multimodality imaging to assist the operation of malignant bone tumors of limbs].

Xiang Fang1, Senlin Lei1, Yi Luo1, Yong Zhou1, Li Min1, Wenli Zhang1, Chongqi Tu1, Hong Duan1.   

Abstract

Objective: To explore the role and effectiveness of three-dimensional (3D) printing technology based on 3D multimodality imaging in surgical treatment of malignant bone tumors of limbs.
Methods: The clinical data of 15 patients with malignant bone tumors of the limbs who met the selection criteria between January 2016 and January 2019 were retrospectively analyzed. There were 6 males and 9 females, with a median age of 34 years (range, 17-73 years). There were 5 cases of osteosarcoma, 3 cases of chondrosarcoma, 2 cases of Ewing sarcoma, 1 case of hemangiosarcoma, 1 case of ameloblastoma, and 3 cases of metastatic carcinoma. The tumors were located in the humerus in 5 cases, ulna in 2 cases, femur in 3 cases, and tibia in 5 cases. The disease duration was 2-8 months (median, 4 months). Preoperative 3D multimodality imaging was administered first, based on which computer-assisted preoperative planning was performed, 3D printed personalized special instruments and prostheses were designed, and in vitro simulation of surgery was conducted, successively. Two cases underwent knee arthroplasty, 2 had semi-shoulder arthroplasty, 2 had proximal ulna arthroplasty, and 9 had joint-preserving surgery. Surgical margins, operation time, intraoperative blood loss, surgical complications, Musculoskeletal Tumor Society (MSTS) score, and oncological outcome were collected and analyzed.
Results: All 15 patients completed the operation according to the preoperative plan, and the surgical margins were all obtained wide resection margins. The operation time was 80-240 minutes, with a median of 150 minutes. The intraoperative blood loss was 100-400 mL, with a median of 200 mL. There was no significant limitation of limb function due to important blood vessels or nerves injury during operation. One case of superficial infection of the incision was cured after dressing change, and the incisions of the other patients healed by first intention. All patients were followed up 6-48 months, with a median of 24 months. Two of the patients died of lung metastasis at 6 and 24 months after operation, respectively. No local recurrence, prosthesis dislocation, or prosthesis loosening occurred during follow-up. At last follow-up, the MSTS score ranged from 23 to 30, with an average of 25.
Conclusion: 3D printing tecnology, based on 3D multimodality imaging, facilitates precise resection and reconstruction for malignant bone tumors of limbs, resulting in improved oncological and functional outcome.

Entities:  

Keywords:  Three-dimensional multimodality imaging; malignant bone tumor; surgical planning; three-dimensional printing technology

Mesh:

Year:  2022        PMID: 35848174      PMCID: PMC9288904          DOI: 10.7507/1002-1892.202202060

Source DB:  PubMed          Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi        ISSN: 1002-1892


  13 in total

1.  Use of Vascularized Fibular Epiphyseal Transfer with Massive Bone Allograft for Proximal Humeral Reconstruction in Children with Bone Sarcoma.

Authors:  Yajie Lu; Xin Xiao; Minghui Li; Guojing Chen; Mengquan Huang; Chuanlei Ji; Zhen Wang; Jing Li
Journal:  Ann Surg Oncol       Date:  2021-05-11       Impact factor: 5.344

Review 2.  Limb salvage for osteosarcoma.

Authors:  M A Simon
Journal:  J Bone Joint Surg Am       Date:  1988-02       Impact factor: 5.284

3.  Surgical management of pelvic bone sarcoma with internal hemipelvectomy: Oncologic and Functional outcomes.

Authors:  Abhijeet Ashok Salunke; Jaymin Shah; Vikas Warikoo; Amit Chakraborty; Harshwardhan Sahijwani; Mohit Sharma; Rohit Jha; Avdhoot Dhange; Subodh Pathak; Jyotindra Pandit; Manish Pruthi; Shashank Pandya; Abhishek Jain
Journal:  J Clin Orthop Trauma       Date:  2017-05-06

4.  3D-Printed Modular Hemipelvic Endoprosthetic Reconstruction Following Periacetabular Tumor Resection: Early Results of 80 Consecutive Cases.

Authors:  Tao Ji; Yi Yang; Xiaodong Tang; Haijie Liang; Taiqiang Yan; Rongli Yang; Wei Guo
Journal:  J Bone Joint Surg Am       Date:  2020-09-02       Impact factor: 5.284

5.  A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system.

Authors:  W F Enneking; W Dunham; M C Gebhardt; M Malawar; D J Pritchard
Journal:  Clin Orthop Relat Res       Date:  1993-01       Impact factor: 4.176

6.  Open Surgery for Osteoid Osteoma with Three Dimensional C-arm Scan under the Guidance of Computer Navigation.

Authors:  Nong Lin; Zhao-Ming Ye; Hao Qu; Xiao-Bo Yan; Wei-Bo Pan; Xin Huang; Meng Liu
Journal:  Orthop Surg       Date:  2016-05       Impact factor: 2.071

7.  Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma.

Authors:  Kevin B Jones; Peter C Ferguson; Brian Lam; David J Biau; Sevan Hopyan; Benjamin Deheshi; Anthony M Griffin; Lawrence M White; Jay S Wunder
Journal:  J Bone Joint Surg Am       Date:  2012-08-01       Impact factor: 5.284

8.  The Personalized Shoulder Reconstruction Assisted by 3D Printing Technology After Resection of the Proximal Humerus Tumours.

Authors:  Hongzhi Hu; Weijian Liu; Qianwen Zeng; Shangyu Wang; Zhicai Zhang; Jianxiang Liu; Yingze Zhang; Zengwu Shao; Baichuan Wang
Journal:  Cancer Manag Res       Date:  2019-12-23       Impact factor: 3.989

9.  One-Step Reconstruction with a Novel Suspended, Modular, and 3D-Printed Total Sacral Implant Resection of Sacral Giant Cell Tumor with Preservation of Bilateral S1-3 Nerve Roots via a Posterior-Only Approach.

Authors:  Zhao-Rui Lv; Zhen-Feng Li; Zhi-Ping Yang; Xin Li; Qiang Yang; Ka Li; Jianmin Li
Journal:  Orthop Surg       Date:  2019-12-18       Impact factor: 2.071

10.  Guideline for Limb-Salvage Treatment of Osteosarcoma.

Authors:  Ming Xu; Zhen Wang; Xiu-Chun Yu; Jian-Hua Lin; Yong-Cheng Hu
Journal:  Orthop Surg       Date:  2020-07-06       Impact factor: 2.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.